CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Pict… Read more
CorMedix Inc (CRMD) - Net Assets
Latest net assets as of September 2025: $374.13 Million USD
Based on the latest financial reports, CorMedix Inc (CRMD) has net assets worth $374.13 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($750.86 Million) and total liabilities ($376.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $374.13 Million |
| % of Total Assets | 49.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | 91.43% |
| 10-Year Change | 148.91% |
| Growth Volatility | 258.08 |
CorMedix Inc - Net Assets Trend (2008–2024)
This chart illustrates how CorMedix Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CorMedix Inc (2008–2024)
The table below shows the annual net assets of CorMedix Inc from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $84.66 Million | +20.69% |
| 2023-12-31 | $70.14 Million | +27.39% |
| 2022-12-31 | $55.06 Million | -12.32% |
| 2021-12-31 | $62.80 Million | +42.00% |
| 2020-12-31 | $44.22 Million | +87.02% |
| 2019-12-31 | $23.65 Million | +379.23% |
| 2018-12-31 | $4.93 Million | -31.41% |
| 2017-12-31 | $7.19 Million | -59.62% |
| 2016-12-31 | $17.81 Million | -47.62% |
| 2015-12-31 | $34.01 Million | +835.80% |
| 2014-12-31 | $3.63 Million | +190.36% |
| 2013-12-31 | $-4.02 Million | -746.14% |
| 2012-12-31 | $-475.38K | -138.44% |
| 2011-12-31 | $1.24 Million | -82.96% |
| 2010-12-31 | $7.26 Million | +149.33% |
| 2009-12-31 | $-14.71 Million | -22.30% |
| 2008-12-31 | $-12.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CorMedix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 32242044500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $64.41K | 0.08% |
| Other Comprehensive Income | $90.65K | 0.11% |
| Other Components | $424.13 Million | 501.00% |
| Total Equity | $84.66 Million | 100.00% |
CorMedix Inc Competitors by Market Cap
The table below lists competitors of CorMedix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guanhao Biotech Co Ltd
SHE:300238
|
$440.30 Million |
|
Time Technoplast Limited
NSE:TIMETECHNO
|
$440.42 Million |
|
Beijing Bayi Space LCD Technology Co Ltd
SHG:688181
|
$440.48 Million |
|
Global Medical REIT Inc.
NYSE:GMRE
|
$440.68 Million |
|
Guangzhou Guangri Stock Co Ltd
SHG:600894
|
$440.17 Million |
|
i3 Verticals Inc
NASDAQ:IIIV
|
$440.17 Million |
|
Flaircomm Microelectronics Inc Ordinary Shares - Class A
SHE:301600
|
$440.13 Million |
|
Greenvolt Energias Renovaveis SA
LS:GVOLT
|
$439.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CorMedix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 70,142,429 to 84,656,950, a change of 14,514,521 (20.7%).
- Net loss of 17,930,020 reduced equity.
- New share issuances of 18,881,587 increased equity.
- Other comprehensive income decreased equity by 3,462.
- Other factors increased equity by 13,566,416.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-17.93 Million | -21.18% |
| Share Issuances | $18.88 Million | +22.3% |
| Other Comprehensive Income | $-3.46K | -0.0% |
| Other Changes | $13.57 Million | +16.03% |
| Total Change | $- | 20.69% |
Book Value vs Market Value Analysis
This analysis compares CorMedix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $-71.41 | $6.46 | x |
| 2009-12-31 | $-85.85 | $6.46 | x |
| 2010-12-31 | $3.83 | $6.46 | x |
| 2011-12-31 | $0.54 | $6.46 | x |
| 2012-12-31 | $-0.21 | $6.46 | x |
| 2013-12-31 | $-1.45 | $6.46 | x |
| 2014-12-31 | $0.85 | $6.46 | x |
| 2015-12-31 | $5.43 | $6.46 | x |
| 2016-12-31 | $2.35 | $6.46 | x |
| 2017-12-31 | $-13.80 | $6.46 | x |
| 2018-12-31 | $-10.05 | $6.46 | x |
| 2019-12-31 | $-8.09 | $6.46 | x |
| 2020-12-31 | $1.55 | $6.46 | x |
| 2021-12-31 | $1.67 | $6.46 | x |
| 2022-12-31 | $1.37 | $6.46 | x |
| 2023-12-31 | $1.38 | $6.46 | x |
| 2024-12-31 | $1.44 | $6.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CorMedix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -41.24%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.40x
- Recent ROE (-21.18%) is above the historical average (-99.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.79 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.65 Million |
| 2010 | -150.31% | 0.00% | 0.00x | 1.22x | $-11.63 Million |
| 2011 | -542.75% | 0.00% | 0.00x | 2.07x | $-6.83 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.38 Million |
| 2013 | 0.00% | -456654.90% | 0.00x | 0.00x | $-8.73 Million |
| 2014 | -562.76% | -10806.25% | 0.04x | 1.40x | $-20.82 Million |
| 2015 | -53.47% | -8655.37% | 0.01x | 1.09x | $-21.59 Million |
| 2016 | -138.33% | -10996.46% | 0.01x | 1.23x | $-26.43 Million |
| 2017 | 0.00% | -10023.45% | 0.02x | 0.00x | $-17.79 Million |
| 2018 | 0.00% | -6242.40% | 0.02x | 0.00x | $-8.93 Million |
| 2019 | 0.00% | -5801.29% | 0.01x | 0.00x | $3.11 Million |
| 2020 | -49.81% | -9207.70% | 0.00x | 1.11x | $-26.45 Million |
| 2021 | -44.92% | -14774.70% | 0.00x | 1.10x | $-34.49 Million |
| 2022 | -53.94% | -45409.90% | 0.00x | 1.13x | $-35.21 Million |
| 2023 | -66.06% | 0.00% | 0.00x | 1.17x | $-53.35 Million |
| 2024 | -21.18% | -41.24% | 0.37x | 1.40x | $-26.40 Million |
Industry Comparison
This section compares CorMedix Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CorMedix Inc (CRMD) | $374.13 Million | 0.00% | 1.01x | $440.19 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |